Multiple eruptive plaque‐like dermatofibromas during anti‐TNFα treatment

Caldarola, Giacomo; Bisceglia, Michele; Pellicano, R.

doi:10.1111/j.1365-4632.2011.05047.x

Cited by 7 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, some cases of clustered or plaque-like dermatofibromas appear to be different from the MCDF/PLDF/PLMT group. Most notable among these are four case reports of patients who also had multiple clustered or plaque-like dermatofibromas that, however, differed by their eruptive time course and, in three cases, by coincidence with the administration of immunosuppressive medication [27][28][29][30]. Our patient clearly does not fit into this group because her plaque exhibited very slow growth, and she had taken immunomodulatory medication only in the recent past.…”

Section: Discussionmentioning

confidence: 73%

Plaque-Like Dermatofibroma: Case Report of a Rare Entity

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 73%

Plaque-Like Dermatofibroma: Case Report of a Rare Entity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cases of MEDF in patients receiving cyclophosphamide, methotrexate, glucocorticoids, and azathioprine have been reported [5]. In 2013, the first case of MEDF that was associated with anti-tumor necrosis factorα (anti-TNF-α) therapy was reported in a patient with rheumatoid arthritis, who was treated with etanercept [8].…”

Section: Discussionmentioning

confidence: 99%

Multiple eruptive dermatofibromas

Callahan

Matires²,

Shvartsbeyn³

et al. 2015

Dermatology Online Journal

View full text Add to dashboard Cite

We report a 34 year-old woman with psoriasis, systemic lupus erythematosus (SLE), and recent anti-TNFa therapy, who presented with multiple, eruptive dermatofibromas (MEDF). Although the pathogenesis of MEDF remains unknown, there is substantial evidence that this phenomenon represents an aberrant immune response. Like the more common presentation of solitary dermatofibromas, these lesions are benign, and no treatment is required. However, MEDF is increasingly recognized as a sign of immune dysregulation and an appropriate work-up should be initiated to identify an underlying cause in patients without a known trigger. Case synopsis HISTORY:A 32-year-old woman was referred to the Dermatology Clinic at Bellevue Hospital Center for the management of psoriasis. She had previously been treated with several systemic medications, which included methotrexate, adalimumab, and etanercept, without success. Most recently, she had been treated with ustekinumab for four months, which was discontinued in the setting of a severe, allergic reaction. Owing to the failure of multiple medications, her dermatologist recommended that she come to our clinic for further management. Apart from mild scale and pruritus of the scalp, she denied any active, psoriatic lesions. However, she did note a six-month history of eruptive, slightly-tender, hyperpigmented papules on her left lower leg and the dorsal aspect of the left foot. The lesions had appeared abruptly within four to five months of one another.Past medical history included systemic lupus erythematosus for which she was treated with prednisone 5mg daily and was followed by the Rheumatology Service. She denied any systemic symptoms, which included weight loss, fevers, chills, fatigue, joint pain, and gastrointestinal symptoms. A shave biopsy was obtained from a lesion on the dorsal aspect of the left foot.Physical examination: Six, small, approximately 5-mm, hyperpigmented, papules were scattered on the left lower leg and the dorsal aspect of the foot. Laboratory data:A complete blood count showed a hemoglobin of 11.5g/mL but was otherwise normal. A metabolic panel was normal.Histopathology: There is a relatively well-circumscribed dermal lesion that is composed of intersecting fascicles of plump fibroblasts, with thick collagen bundles at its periphery. The overlying epidermis is hyperplastic.

show abstract

“…Es wird angenommen, dass es sich beim Dermatofibrom um einen reaktiven Prozess aufgrund der dauerhaften Proliferation von Fibroblasten nach einem Trauma handelt [3]. Diese Hypothese wird durch unsere Studie unterstützt [5, 71–73]. Allerdings wurden multiple DF stark mit einer zugrundeliegenden Erkrankung assoziiert.…”

Section: Diskussionunclassified

Klinische und histologische Charakteristika bei multiplen Dermatofibromen: Eine systematische Übersicht

Seifi

Kalantari

Etesami

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Multiple Dermatofibrome (DF) sind seltene gutartige fibrohistiozytäre Läsionen, die durch asymptomatische hyperpigmentierte Knoten charakterisiert sind. Mehrere Erkrankungen wie systemischer Lupus erythematodes (SLE) und Infektionen mit dem humanen Immundefizienz‐Virus (HIV) sind mit multiplen DF assoziiert. Hier haben wir eine systematische Übersicht anhand einer elektronischen Recherche der Datenbanken PubMed und Embase konzipiert, um Fallberichte zu multiplen DF auszuwählen (29. Mai 2021). Von den 2145 ursprünglich gefundenen Artikeln wurden 96 Studien (106 Fälle) eingeschlossen. Multiple DF (> 1 DF‐Läsion) wurden in vier Subtypen eingeteilt und für jeden Subtyp wurden die klinischen Charakteristika separat untersucht: multiple eruptive DF (MEDF) (n = 45), multiple DF (n = 41), multiple gruppierte DF (MCDF) (n = 18) und große kombinierte DF (n = 2). Das Durchschnittsalter der Patienten betrug 38,3 ± 14,7 Jahre. Die Mehrzahl waren Frauen (61,3 %). Die Läsionen befanden sich häufig am Stamm und an den Extremitäten (36,8 %). MEDF (n = 36) hatten den schnellsten Krankheitsbeginn (2,0 ± 6,6 Jahre). Neben SLE (19,8 %) war eine durch HIV (10,3 %), maligne hämatologische Erkrankungen (9,4 %) oder Immunsuppressiva (23,4 %) induzierte Immunsuppression die am häufigsten beobachtete Assoziation. Allerdings waren 66,7 % der MCDF‐Patienten ansonsten gesund. Hinsichtlich des Managements der Erkrankung waren Operation und Nachkontrolle die bevorzugten Optionen. Bei den meisten Fällen trat während der Nachkontrolle weder eine Abheilung noch eine Entwicklung neuer Läsionen auf.

show abstract

Multiple eruptive plaque‐like dermatofibromas during anti‐TNFα treatment

Cited by 7 publications

References 7 publications

Plaque-Like Dermatofibroma: Case Report of a Rare Entity

Plaque-Like Dermatofibroma: Case Report of a Rare Entity

Multiple eruptive dermatofibromas

Klinische und histologische Charakteristika bei multiplen Dermatofibromen: Eine systematische Übersicht

Contact Info

Product

Resources

About